Contact details
Uschi Mayer
External Communications
Mobile: +43 676 84 68 68 966
E-mail: uschi.mayer@croma.at
press releases
2023
-
Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets
-
Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter
-
Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators
-
AMWC 2023: Croma-Pharma to present recent clinical data and new range of skin boosters
-
Daniela Rudowitz New Global Medical Director
2022
-
Croma completes launch of its botulinum toxin in eleven European markets
-
Croma-Pharma is expanding its management team
-
Croma-Pharma completed the decentralized procedure for its botulinum toxin to treat glabellar (frown) lines
2021
-
Croma-Pharma presents juvenus, a new polynucleotide based injectable for skin hydration and tissue elasticity restoration
-
Croma-Pharma expands successful mask range with face masks for different areas of application
-
Croma-Pharma Announces 9-Country Licensing Agreement with Crescita Therapeutics for Pliaglis®
-
Croma-Pharma presents new cosmetic skincare brand "Croma farewell™" for common skin conditions
2020
-
Croma establishes new Joint Venture in China
-
Croma-Pharma GmbH expands its portfolio introducing pure HA
-
Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM
-
BVI forges strategic partnership with Croma-Pharma
-
Croma-Pharma supports Light for the World
2019
-
Croma-Pharma GmbH establishes affiliate in UK
-
Croma-Pharma reveals new packaging design for the Arthrex ACP® double syringe system
-
Croma-Pharma GmbH expands its portfolio introducing elure
-
Croma-Pharma reveals new packaging design for the Arthrex ACP® double syringe system
2018
-
Croma-Pharma completes rebranding of its HA filler range
-
Innovation Award for Croma-Pharma
